期刊文献+

晚期非小细胞肺癌四种化疗方案的最小成本分析 被引量:6

Cost-minimization Analysis of Four Chemotherapy Regimens for Advanced Non-small Cell Lung Cancer
原文传递
导出
摘要 [目的]对比并评价四种化疗方案对晚期非小细胞肺癌的治疗效果、不良反应以及药物经济学。[方法]将60例晚期非小细胞肺癌患者按化疗方案不同分为PC组(紫杉醇+卡铂)、NP组(长春瑞滨+顺铂)、GP组(吉西他滨+顺铂)和TP组(多西他赛+顺铂)。四组均行2个周期化疗且每个周期为21d。观察并对比四种化疗方法的临床疗效和不良反应,运用药物经济学原理对四组进行最小成本分析。[结果]PC、NP、GP和TP四组的总有效率分别为37.5%(6/16)、35.7%(5/14)、40.0%(6/15)和40.0%(6/15),差异无统计学意义(P>0.05);四组消化道综合征、白细胞水平降低、血红蛋白水平降低、血小板计数减少、肝肾功能异常、脱发等不良反应发生率比较差异均无统计学意义(P>0.05);PC、NP、GP和TP组的总成本分别为(5829.9±2184.7)元、(5101.5±1694.0)元、(9310.8±3057.4)元和(6798.7±2409.9)元,四组总成本由高至低为GP组>TP组>PC组>NP组,GP组与其他三组比较差异均具有统计学意义(P<0.05);进行敏感度分析,结果相同。[结论]最小成本分析显示采用TP、PC、NP方案治疗晚期非小细胞肺癌疗效相当,可最大限度提高药物资源在临床的利用和配置的效率。 [Purpose] To compare and evaluate the clinical efficacy,adverse reaction and pharmacoeconomic effect of four kinds of chemotherapy regimens on treatment of non-small cell lung cancer(NSCLC). [Methods] According to the different chemotherapy regimen,60 cases hospitalized patients with NSCLC were divided into PC group(paclitaxel and carboplatin),NP group(vinorelbine and cisplatin),GP group(gemcitabine and cisplatin) and TP group(docetaxel and cisplatin). Each group was undergone two cycles of chemotherapy whose period was 21 days. The clinical efficacy and adverse reaction of four kinds of chemotherapy regimens were observed and compared,and the cost-minimization was analyzed by pharmacoeconomic theory.[Results] The total efficiency of the PC group,NP group,GP group and TP group were 37.5%(6/16),35.7%(5/14),40.0%(6/15) and 40.0%(6/15),respectively. There was no statistical difference in four groups(P〉0.05). The adverse reaction in four groups were gastrointestinal syndrome,lower white blood cell level,lower hemoglobin levels,lower platelet count,liver and kidney dysfunction and alopecia,and all the incidence of adverse reactions of four groups had no significant difference( P〉0. 05). The costs of PC group, NP group, GP group and TP group were5829.9±2184.7 yuan,5101.5±1694.0 yuan,9310.8 ±3057.4 yuan and 6798.7 ±2409.9 yuan,respectively. The costs of four groups from high to low were GP group,TP group,PC group and NP group. The differences between GP group compared with other three groups was statistically significant(P〉0.05). After the sensitivity analysis,the results were still the same. [Conclusions]The cost-minimization shows that the chemotherapy methods in TP group,PC group and GP group have the same clinical efficacies. They can improve the utilization and allocation efficien-cy of pharmaceutical resources in clinical to the maximum extent.
出处 《肿瘤学杂志》 CAS 2015年第8期645-650,共6页 Journal of Chinese Oncology
基金 山东省临沂市2014年度科学发展计划卫生专项(201413081)
关键词 非小细胞肺 化学药物疗法 成本分析 non-small cell lung cancer chemotherapy pharmacoeconomics
  • 相关文献

参考文献15

  • 1Lin XL, Chen Y, Gong WW, et al. Geographic distribution and epidemiology of lung cancer during 2011 in Zhejiang province of China[J]. Asian Pacific Journal of Cancer Prevention : APJCP, 2014,15(13) : 5299-5303.
  • 2Zugazagoitia J,Enguita AB, Nnnez JA,et al. The new iaslc/ats/ers lung adenocarcinoma classification from a clinical perspective:current concepts and future prospects [J]. Thorac Dis, 2014,6(Suppl 5) : $526-$536.
  • 3Sun YH,Lin SW,Hsieh CC,et al. Treatment outcomes of patients with different subtypes of large cell carcinoma of the lung[J]. Ann Thorac Surg,2014,98(3): 1013-1019.
  • 4Mutlu H,Buyukcelik A,Aslan T,et al. The optimal chemotherapy timing in patients with inoperable locally advanced non small cell lung cancer[J]. Med Arch,2013, 67(2) : 104-106.
  • 5Song Z,Zhn H,Guo Z,et al. Prognostic value of the iaslc/ ats/ers classification in stage I lung adenocarcinoma pa- tients-based on a hospital study in China[J]. Eur J Surg Oneol, 2013,39(11) : 1262-1268.
  • 6Jang HJ,Cho JW,Park B,et al. The assessment of tumor response by measuring the single largest lesion per organ in metastatic tumors:a pooled analysis of previously re- ported data[J]. J Cancer, 2015,6(2) : 169-176.
  • 7Ruan M,Shen Y,Chen L,et al. Recist 1.1 and serum thyroglobulin measurements in the evaluation of responses to sorafenib in patients with radioactive iodine-refractory differentiated thyroid carcinoma[J]. Oncol Lett, 2013,6(2) : 480-486.
  • 8Franklin HR, Simonetti GP, Dubbelman AC, et al. Toxicity grading systems. A comparison between the who scoringsystem and the common toxicity criteria when used for nausea and vomiting[J]. Ann Oncol:Official Journal of the European Society for Medical Oncology/ESMO,1994,5 (2): 113-117.
  • 9Grossi F. Management of non-small cell lung in cancer patients with stable disease [J]. Drugs,2012,72 Suppl 1 : 20-27.
  • 10Non-small cell lung cancer collaborative group. Chemotherapy in non-small cell lung cancer:a meta-analysis using updated data on individual patients from 52 ran- domised clinical trials[J]. BMJ, 1995,311 (7010) : 899-909.

二级参考文献15

  • 1Schiller JH,Harrington D,Belani CP,et al.Comparison of four chemotherapy regimens for advanced non-small cell lung cancer[J].N Engl J Med,2002,346(2):92-98.
  • 2Scagliotti GV,De Marinis F,Rinaldi M,et al.Phase Ⅲ randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cance r[J].J Clin Oncol,2002,20(21):4 285-4 291.
  • 3Reck M.Current approaches in chemotherapy of advanced and metastatic non-small cell lung cancer (NSCLC)[J].Anticancer Res,2005,25(3A):1 501-1 5 06.
  • 4Ettinger DS.Is there a preferred combination chemotherapy regimen for metastastic non-small cell lung cancer?[J].Oncologist,2002,7(3):226-233.
  • 5Novello S,Kielhorn A,Stynes G,et al.Cost-minimisation analysis compa ring gemcitabine/cisplation,paclitaxel/carboplation and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy[J].Lung Cancer,2005,48(3):379-387.
  • 6Schiller J,Tilden D,Aristides M,et al.Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe[J].Lung Cancer,2004,43(1):101-102.
  • 7Clegg A,Scott DA,Sidhu M,et al.A rapid and systemic review of clinical effectiveness and cost effectiveness of paclitaxel,docetaxel,gemcitabine and vinorelbine in non-small cell lung cancer[J].Health Technol Assess,2001,5(32):1-193.
  • 8Herrstedt J,Aapro MS,Roila F,et al.ESMO minimum clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV)[J].Ann On col,2005,16(Suppl 1):77-79.
  • 9Ozer H,Armitage JO,Bennett CL,et al.2000 update of recommendations for the use of hematopoietic colony-stimulating factors:evidence-based,clinical practice guidelines.American Society of Clinical Oncology Growth Factors Expert Panel[J].J Clin Oncol,2000,18(20):3 558-3 585.
  • 10British Committee for Standards in Haematology,Blood Tran sfusion Task Forc e.Guidelines for the use of platelet transfusions[S].Br J Haematol,2003,1 22(1):10-23.

共引文献28

同被引文献76

  • 1杨学宁,吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学,2004,4(2):85-90. 被引量:1572
  • 2谭诗生,李杭,罗健,陈南江,宋毅,姜桂林,杨飞月.欧洲癌症研究与治疗组织研制的生活质量核心调查问卷第3版中文版生活质量调查问卷测评[J].中国临床康复,2006,10(4):23-27. 被引量:315
  • 3Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl ]" Med, 2002, 346(2): 92-98.
  • 4Ozkan Y, Yardim-Akaydin S, Firat HA, et al. Usefulness of homocysteine as a cancer marker: total thiol compounds and folate levels in untreated lung cancer patients[J]. Anticancer Res, 2007, 27(2): 1185-1189.
  • 5Kohaar I, Kumar J, Thakur N, et al. Homocysteine levels are associated with cervical cancer independent of methylene tetrahydrofolate reductase gene (MTHFR) polymorphisms in Indian population[J]. Biomarkers, 2010, 15(1): 61-68.
  • 6Hanagiri T, Sugaya M, Takenaka M, et al. Preoperative tSY tKA zi-I and CEA as prognostic factors in patients with stage I non-small cell lung cancer[J]. Lung Cancer, 2011, 74(1): 112-117.
  • 7Cedrs S, Nufiez I, Longo M, et al. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC)[J]. Clin Lung Cancer, 2011, 12(3): 172-179.
  • 8Baltar VT, Xun WW, Iohansson M, et al. A structural equation modelling approach to explore the role of B vitamins and immune markers in lung cancer risk[J]. Eur J Epidemiol, 2013, 28(8): 677-688.
  • 9Cui LH, Yu Z, Zhang TT, et al. Influence of polymorphisms in MTHFR 677 C->T, TYMS 3R->2R and MTR 2756 A→G on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC[J]. Pharmacogenomics, 201 1, 12(6): 797-808.
  • 10李秀云,陈美一,马利国,刘雪婧.宫颈浸润癌患者术后生存质量调查分析[J].海南医学,2010,21(15):122-124. 被引量:4

引证文献6

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部